UNSPSC 51351522: Chlormadinone acetate

This classification denotes a therapeutic progestin with the molecular formula C23H29ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0SY050L61N, chemically known as 17.alpha.-acetoxy-6-chloro-4, 6-pregnadiene-3,20-dione but more generally known as chlormadinone acetate, which bears US NIH Compound Identifier 2714. European Medicines Agency schedules Chlormadinone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01219MIG.

UNSPSC 51351522 Chlormadinone acetate is a Commodity code covering synthetic progestin pharmaceutical products supplied through state and local procurement channels, though recent activity shows this code capturing broader generic multi-source pharmaceutical and over-the-counter product sourcing rather than chlormadinone acetate specifically. State and local government buyers — primarily state health and human services departments, correctional facilities, and institutional healthcare systems participating in cooperative purchasing alliances — use this code to procure prescription and non-prescription medications for patient care and institutional use. The solicitations emphasize manufacturers and authorized distributors capable of meeting cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and FDA requirements, with products requiring minimum one-year expiration dates and six-month shelf life from manufacture.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the primary recent activity under this code: an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline and July 1, 2026 contract effective date. MMCAP solicits on behalf of participating state and local government facilities across multiple states, including Oregon. The RFP requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of the three, and demonstrate pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. The contract term spans two years for new vendors with optional MMCAP extensions, or alignment with existing expiration dates through June 30, 2028 for incumbents.